Clinical Trial Update: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) [Phase 2]

View source ↗

Summary

Phase 2 trial update on the efficacy and safety of Nemtabrutinib (MK-1026) in hematologic malignancies, including Waldenström macroglobulinemia, non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Nemtabrutinib (nemtabrutinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hematologic Malignancies, Waldenstroms Macroglobulinaemia | Phase 2 | Status: RECRUITING